Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines

Claus Roehrborn

doi:10.1159/000473819

Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines

Claus Roehrborn

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The effectiveness and safety of a-adrenergic blockade for the treatment of BPH has been demonstrated in large-scale, randomized, placebo-controlled, multicenter trials. Good patient compliance, low failure or retreatment rates, and cost-effectiveness have also been shown. Moreover, therapeutic success has been independent of the healthcare provider or venue. Accordingly, both the Agency for Health Care Policy and Research (AHCPR) and the 3rd International Consultation on BPH have recognized α₁-specific adrenergic receptor blockers as a reasonable treatment alternative for men with symptomatic BPH.

Original language	English (US)
Pages (from-to)	40-48
Number of pages	9
Journal	European urology
Volume	29
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000473819
State	Published - Jan 1 1996

Keywords

Alpha-blocker
Benign prostatic hyperplasia
Treatment guidelines

ASJC Scopus subject areas

Urology

Access to Document

10.1159/000473819

Cite this

@article{4e3864ef41e44911a0b5eb64b28845e0,

title = "Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines",

abstract = "The effectiveness and safety of a-adrenergic blockade for the treatment of BPH has been demonstrated in large-scale, randomized, placebo-controlled, multicenter trials. Good patient compliance, low failure or retreatment rates, and cost-effectiveness have also been shown. Moreover, therapeutic success has been independent of the healthcare provider or venue. Accordingly, both the Agency for Health Care Policy and Research (AHCPR) and the 3rd International Consultation on BPH have recognized α1-specific adrenergic receptor blockers as a reasonable treatment alternative for men with symptomatic BPH.",

keywords = "Alpha-blocker, Benign prostatic hyperplasia, Treatment guidelines",

author = "Claus Roehrborn",

year = "1996",

month = jan,

day = "1",

doi = "10.1159/000473819",

language = "English (US)",

volume = "29",

pages = "40--48",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines

AU - Roehrborn, Claus

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The effectiveness and safety of a-adrenergic blockade for the treatment of BPH has been demonstrated in large-scale, randomized, placebo-controlled, multicenter trials. Good patient compliance, low failure or retreatment rates, and cost-effectiveness have also been shown. Moreover, therapeutic success has been independent of the healthcare provider or venue. Accordingly, both the Agency for Health Care Policy and Research (AHCPR) and the 3rd International Consultation on BPH have recognized α1-specific adrenergic receptor blockers as a reasonable treatment alternative for men with symptomatic BPH.

AB - The effectiveness and safety of a-adrenergic blockade for the treatment of BPH has been demonstrated in large-scale, randomized, placebo-controlled, multicenter trials. Good patient compliance, low failure or retreatment rates, and cost-effectiveness have also been shown. Moreover, therapeutic success has been independent of the healthcare provider or venue. Accordingly, both the Agency for Health Care Policy and Research (AHCPR) and the 3rd International Consultation on BPH have recognized α1-specific adrenergic receptor blockers as a reasonable treatment alternative for men with symptomatic BPH.

KW - Alpha-blocker

KW - Benign prostatic hyperplasia

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=0029925552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029925552&partnerID=8YFLogxK

U2 - 10.1159/000473819

DO - 10.1159/000473819

M3 - Article

AN - SCOPUS:0029925552

SN - 0302-2838

VL - 29

SP - 40

EP - 48

JO - European urology

JF - European urology

IS - SUPPL. 1

ER -

Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this